Related Experiment Video
Updated: Jun 8, 2026
03:45
Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Hypertrophic cardiomyopathy in childhood
1Department of Cardiology, Children's Hospital Boston, 300 Longwood Avenue, Boston, MA 02115, USA. colan@alum.mit.edu
Heart Failure Clinics
|September 28, 2010
Summary
Hypertrophic cardiomyopathy in children differs significantly from adults, with survival depending on the cause. Genetic testing in familial hypertrophic cardiomyopathy offers crucial insights for pediatric patient management.
Area of Science:
- Pediatric Cardiology
- Genetics
- Cardiovascular Disease
Background:
- Hypertrophic cardiomyopathy (HCM) presents unique challenges in pediatric populations compared to adults.
- Etiology significantly impacts survival rates, especially in infants and young children.
- Understanding age-specific risk/benefit ratios is crucial for managing pediatric HCM.
Purpose of the Study:
- To highlight the distinct features of pediatric hypertrophic cardiomyopathy.
- To emphasize the necessity of identifying the specific cause of HCM in children.
- To underscore the clinical utility and cost-effectiveness of genotypic analysis in familial HCM.
Main Methods:
- Comparative analysis of pediatric versus adult hypertrophic cardiomyopathy.
- Review of survival data correlated with etiology in young patients.
- Evaluation of the clinical utility and cost-benefit of genetic testing in familial HCM.
Main Results:
- Pediatric hypertrophic cardiomyopathy exhibits a broader range of causes and varied outcomes compared to adults.
- Survival in infants with HCM is strongly linked to its underlying cause.
- Genotype determination in pediatric familial HCM provides significant clinical value with a favorable cost-benefit ratio.
Conclusions:
- Identifying the specific etiology of hypertrophic cardiomyopathy is essential for optimizing survival in pediatric patients.
- Genetic analysis is particularly valuable in children with familial HCM, offering significant clinical utility.
- Treatment and sudden death prevention strategies for pediatric HCM must account for age-specific risk-benefit considerations.
Related Concept Videos
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
01:25Cardiomyopathy I: Introduction and Classification
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
01:26Cellular Adaptation II: Hypertrophy
Hypertrophy is the increase in the size of individual cells, resulting in the enlargement of a tissue or organ. Unlike hyperplasia, which involves an increase in cell number, hypertrophy is characterized by an increase in cell volume. This process often occurs in response to higher functional demand or hormonal stimulation, leading to the production of more structural proteins and organelles, thereby enhancing the cells' work capacity.There are two primary types of hypertrophy: physiological...